Complement Activation May Define a Refractory Subset of Adult ITP
Complement deposition on platelets identifies a biologically distinct subset of adult ITP associated with higher platelet turnover and more first-line treatment refractoriness.
Posted inHematology-Oncology news Pediatrics Public Health
New Statistical Model Predicts Chronic ITP in Children at Diagnosis
A novel statistical model predicts chronic immune thrombocytopenia (ITP) in children at diagnosis, using age, sex, immunoglobulin levels, and lab values, offering early clinical guidance.
Posted inHematology-Oncology Internal Medicine news
Iptacopan Demonstrates Clinical Efficacy in Cold Agglutinin Disease While Falling Short in Immune Thrombocytopenia: Results from a Phase 2 Basket Trial
This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocytopenia.
Posted inHematology-Oncology Internal Medicine news
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thrombocytopenia (ITP) compared to eltrombopag alone.
Posted inHematology-Oncology Internal Medicine news
B-Cell Depletion Meets TPO-RA: Ianalumab and Eltrombopag Redefine Treatment Success in Immune Thrombocytopenia
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering a route toward sustained, treatment-free remission.
Posted inHematology-Oncology news
CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial
The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.
Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.